Effectiveness and safety of Glucosamine, chondroitin, the two in combination, or celecoxib in the treatment of osteoarthritis of the knee

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Zeng, Chao ^a   Wei, Jie ^a,b   Li, Hui ^a   Wang, Yi Lun ^a   Xie, Dong Xing ^a   Yang, Tuo ^a   Gao, Shu Guang ^a   Li, Yu Sheng ^a   Luo, Wei ^a   Lei, Guang Hua ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CHONDROITIN; GLUCOSAMINE;

ANALGESIA; ARTHRALGIA; COMBINATION DRUG THERAPY; COMPLICATION; HUMAN; META ANALYSIS; ODDS RATIO; OSTEOARTHRITIS, KNEE; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ARTHRALGIA; CELECOXIB; CHONDROITIN; DRUG THERAPY, COMBINATION; GLUCOSAMINE; HUMANS; ODDS RATIO; OSTEOARTHRITIS, KNEE; PAIN MANAGEMENT; TREATMENT OUTCOME;

EID: 84947250412     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16827     Document Type: Article

References (50)

1. Glyn-Jones, S. et al. Osteoarthritis. Lancet. (2015).
2. Hochberg, M. C. et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 64, 465-474 (2012).
3. Jevsevar, D. S. Treatment of osteoarthritis of the knee: Evidence-based guideline, 2nd edition. J Am Acad Orthop Surg. 21, 571-576 (2013).
4. McAlindon, T. E. et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 22, 363-388 (2014).
5. Dahmer, S. & Schiller, R. M. Glucosamine. Am. Fam. Physician. 78, 471-476 (2008).
6. Yang, S., Eaton, C. B., McAlindon, T. E. & Lapane, K. L. Effects of glucosamine and chondroitin supplementation on knee osteoarthritis: An analysis with marginal structural models. Arthritis Rheumatol. 67, 714-723 (2015).
7. Zarraga, I. G. & Schwarz, E. R. Coxibs and heart disease: What we have learned and what else we need to know. J. Am. Coll. Cardiol. 49, 1-14 (2007).
8. European Medicines Agency. EMEA public statement on the suspension of the marketing authorisation for Bextra (valdecoxib) in the European Union [online]. (2005) Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Public-statement/2009/12/WC500018391.pdf. (Date of access: 01/03/2015).
9. Gong, L. et al. Celecoxib pathways: Pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 22, 310-318 (2012).
10. Hochberg, M. C. et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: A multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann. Rheum. Dis. (2015).
11. Zeng, C. et al. Comparison between 200 mg QD and 100 mg BID oral celecoxib in the treatment of knee or hip osteoarthritis. Sci Rep. 5, 10593 (2015).
12. Wandel, S. et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee. Network meta-analysis. BMJ. 341, c4675 (2010).
13. Zeng, C. et al. Effectiveness of continuous and pulsed ultrasound for the management of knee osteoarthritis: A systematic review and network meta-analysis. Osteoarthr. Cartilage. 22, 1090-1099 (2014).
14. Zeng, C. et al. Electrical stimulation for pain relief in knee osteoarthritis: Systematic review and network meta-analysis. Osteoarthr. Cartilage. 23, 189-202 (2015).
15. Caldwell, D. M., Ades, A. E. & Higgins, J. P. Simultaneous comparison of multiple treatments: Combining direct and indirect evidence. BMJ. 331, 897-900 (2005).
16. Caldwell, D. M., Welton, N. J. & Ades, A. E. Mixed treatment comparison analysis provides internally coherent treatment effect estimates based on overviews of reviews and can reveal inconsistency. J. Clin. Epidemiol. 63, 875-882 (2010).
17. Lumley, T. Network meta-analysis for indirect treatment comparisons. Stat. Med. 21, 2313-2324 (2002).
18. Lu, G. & Ades, A. E. Combination of direct and indirect evidence in mixed treatment comparisons. Stat. Med. 23, 3105-3124 (2004).
19. Bucher, H. C., Guyatt, G. H., Griffith, L. E. & Walter, S. D. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J. Clin. Epidemiol. 50, 683-691 (1997).
20. The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. Available at: www.cochrane-handbook.org. (Date of access: 01/03/2015).
21. Juni, P., Reichenbach, S. & Dieppe, P. Osteoarthritis: Rational approach to treating the individual. Best Pract Res Clin Rheumatol. 20, 721-740 (2006).
22. Nuesch, E. et al. The effects of excluding patients from the analysis in randomised controlled trials: Meta-epidemiological study. BMJ. 339, b3244 (2009).
23. Bannuru, R. R. et al. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: A systematic review and network meta-analysis. Ann. Intern. Med. 162, 46-54 (2015).
24. Pham, T. et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage. 12, 389-399 (2004).
25. Cipriani, A., Higgins, J. P., Geddes, J. R. & Salanti, G. Conceptual and technical challenges in network meta-analysis. Ann. Intern. Med. 159, 130-137 (2013).
26. Trelle, S. et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: Network meta-analysis. BMJ. 342, c7086 (2011).
27. Wu, H. Y. et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: Systematic review and bayesian network meta-analysis. BMJ. 347, f6008 (2013).
28. Chaimani, A., Higgins, J. P., Mavridis, D., Spyridonos, P. & Salanti, G. Graphical tools for network meta-analysis in STATA. PLoS One. 8, e76654 (2013).
29. Dias, S., Welton, N. J., Caldwell, D. M. & Ades, A. E. Checking consistency in mixed treatment comparison meta-analysis. Stat. Med. 29, 932-944 (2010).
30. Salanti, G., Ades, A. E. & Ioannidis, J. P. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: An overview and tutorial. J. Clin. Epidemiol. 64, 163-171 (2011).
31. Begg, C. B. & Mazumdar, M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 50, 1088-1101 (1994).
32. Henrotin, Y., Mobasheri, A. & Marty, M. Is there any scientifi c evidence for the use of glucosamine in the management of human osteoarthritis. Arthritis Res. Ther. 14, 201 (2012).
33. Henrotin, Y. & Lambert, C. Chondroitin and glucosamine in the management of osteoarthritis: An update. Curr. Rheumatol. Rep. 15, (2013).
34. Bottegoni, C., Muzzarelli, R. A. A., Giovannini, F., Busilacchi, A. & Gigante, A. Oral chondroprotection with nutraceuticals made of chondroitin sulphate plus glucosamine sulphate in osteoarthritis. Carbohyd. Polym. 109, 126-138 (2014).
35. Chan, P. S., Caron, J. P. & Orth, M. W. Effect of glucosamine and chondroitin sulfate on regulation of gene expression of proteolytic enzymes and their inhibitors in interleukin-1-challenged bovine articular cartilage explants. Am. J. Vet. Res. 66, 1870-1876 (2005).
36. Chan, P. S., Caron, J. P. & Orth, M. W. Effects of glucosamine and chondroitin sulfate on bovine cartilage explants under long-term culture conditions. Am. J. Vet. Res. 68, 709-715 (2007).
37. Chan, P. S., Caron, J. P., Rosa, G. J. & Orth, M. W. Glucosamine and chondroitin sulfate regulate gene expression and synthesis of nitric oxide and prostaglandin E(2) in articular cartilage explants. Osteoarthritis Cartilage. 13, 387-394 (2005).
38. Fransen, M. et al. Glucosamine and chondroitin for knee osteoarthritis: A double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens. Ann. Rheum. Dis. 74, 851-858 (2015).
39. Nallamothu, B. K., Hayward, R. A. & Bates, E. R. Beyond the randomized clinical trial: The role of effectiveness studies in evaluating cardiovascular therapies. Circulation. 118, 1294-1303 (2008).
40. Mant, J., Dawes, M. & Graham-Jones, S. Randomised controlled trials in general practice. Internal validity of trials is more important than generalisability. BMJ. 312, 779 (1996).
41. Yang, S., Eaton, C. B., McAlindon, T. E. & Lapane, K. L. Effects of glucosamine and chondroitin supplementation on knee osteoarthritis: An analysis with marginal structural models. Arthritis Rheumatol. 67, 714-723 (2015).
42. Martel-Pelletier, J. et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: Data from the osteoarthritis initiative progression cohort. Ann. Rheum. Dis. 74, 547-556 (2015).
43. Bertin, P. & Taieb, C. NSAID-sparing effect of glucosamine hydrochloride in patients with knee osteoarthritis: An analysis of data from a French database. Curr. Med. Res. Opin. 30, 271-277 (2014).
44. Galvin, R. et al. Prescribing patterns of glucosamine in an older population: A national cohort study. BMC Complement Altern Med. 13, 316 (2013).
45. Pendleton, A. et al. EULAR recommendations for the management of knee osteoarthritis: Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann. Rheum. Dis. 59, 936-944 (2000).
46. Jordan, K. M. et al. EULAR Recommendations 2003: An evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann. Rheum. Dis. 62, 1145-1155 (2003).
47. Zhang, W. et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part I: Critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthr. Cartilage. 15, 981-1000 (2007).
48. Zhang, W. et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 16, 137-162 (2008).
49. Zhang, W. et al. OARSI recommendations for the management of hip and knee osteoarthritis. Osteoarthr. Cartilage. 18, 476-499 (2010).
50. Clegg, D. O. et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N. Engl. J. Med. 354, 795-808 (2006).